CD25+ CD4+ regulatory T-cells in cancer

Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor en...

Full description

Saved in:
Bibliographic Details
Published in:Immunologic research 2005-01, Vol.32 (1-3), p.155-168
Main Authors: Linehan, David C, Goedegebuure, Peter S
Format: Article
Language:English
Subjects:
Animals
Autoimmune diseases
Biomarkers, Tumor - immunology
Breast Neoplasms - immunology
Cancer
Cancer Vaccines - therapeutic use
Carcinoma, Ductal, Breast - immunology
CD4 Antigens - metabolism
Dendritic Cells - immunology
Dendritic Cells - pathology
Female
Forkhead Transcription Factors - deficiency
Forkhead Transcription Factors - genetics
Forkhead Transcription Factors - immunology
Humans
Immune Tolerance
Immunology
Lymphocyte Depletion
Medical research
Mice
Mice, Knockout
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Phenotype
Receptors, Interleukin-2 - metabolism
T cell receptors
T-Lymphocytes, Regulatory - immunology
Transforming Growth Factor beta - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accrual of Treg through several mechanisms involving activation of naturally occurring Treg as well as conversion of non-Treg into Treg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.
ISSN:0257-277X
0257-277X
1559-0755
DOI:10.1385/IR:32:1-3:155